RxDoctor Payments Data

Bakul Desai, MD

Cardiovascular Disease · Jersey City, NJNPI 1376654624

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 29 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$671
  • Merck$157
  • Amgen$126
  • G Medical Diagnostic Services, Inc.$29
  • Novartis$23
  • Edwards Lifesciences$23
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$1,066100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott5$671
Merck9$157
Amgen9$126
G Medical Diagnostic Services, Inc.2$29
Novartis1$23
Edwards Lifesciences1$23
Pfizer1$20
Alnylam Pharmaceuticals Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$136,202
Medicare patients
75
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$36,216
EntrestoSacubitril/Valsartan20$22,451
VascepaIcosapent Ethyl13$13,389
Nebivolol Hcl65$2,794
Valsartan64$2,249
Olmesartan Medoxomil15$1,362
Diclofenac Sodium19$752
Metoprolol Succinate43$725
Ezetimibe16$498
Atorvastatin Calcium36$399
Amlodipine Besylate55$313
Digoxin14$285
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$239
ClopidogrelClopidogrel Bisulfate20$216
Tamsulosin Hcl11$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$36,21627 claims
NovartisEntresto$23$22,45120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →